DICE实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (9 Aug 2023 @ 04:00):

DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas...

Stats
今日成交量	4.33M
平均成交量	1.75M
市值	2.27B
EPS	$0 ( 2024-03-14 )
下一个收益日期	( $0 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-21.91
ATR14	$0.513 (1.08%)

Insider Trading

Date	Person	Action	Amount	type
2023-08-09	Ra Capital Management, L.p.	Sell	786 407	Common Stock
2023-08-09	Ra Capital Management, L.p.	Sell	21 250	Stock Option (Right to Buy)
2023-08-09	Tetlow Sharon	Sell	49 841	Common Stock
2023-08-09	Tetlow Sharon	Sell	13 800	Stock Option (right to buy)
2023-08-09	Tetlow Sharon	Sell	21 250	Stock Option (right to buy)

INSIDER POWER
-56.66
Last 99 transactions
Buy: 13 025 781 \| Sell: 10 716 392

音量相关性

長: 0.25 (neutral)

短: 0.00 (neutral)

Signal:(77.583) Neutral

DICE Therapeutics, Inc. 相关性

10 最正相关
MRNS	0.883
DGNU	0.879
ABCM	0.863
ABEO	0.86
SKYW	0.86
SINO	0.859
FSFG	0.858
CGNT	0.858
DFH	0.855
IRBT	0.851

10 最负相关
WYNN	-0.869
MCFT	-0.869
LIBY	-0.867
LSCC	-0.866
ASUR	-0.865
TGLS	-0.864
ULTA	-0.863
KYCH	-0.863
ARYD	-0.863
LAKE	-0.863

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

DICE Therapeutics, Inc. 相关性 - 货币/商品

-0.72
( moderate negative )

-0.74
( moderate negative )

0.36
( neutral )

-0.75
( moderate negative )

-0.13
( neutral )

0.68
( moderate )

DICE Therapeutics, Inc. 财务报表

Annual	2022
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-2.07

FY	2022
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-2.07

FY	2021
营收:	$1.13M
毛利润:	$1.13M (100.00 %)
EPS:	$-2.11

FY	2020
营收:	$863 000
毛利润:	$0.00 (0.00 %)
EPS:	$-1.020

Financial Reports:

No articles found.

DICE Therapeutics, Inc.

DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17, which is a validated drug target implicated in a various immunology indications. It is also developing oral therapeutic candidates targeting a4ß7 integrin for the treatment of inflammatory bowel diseases, as well as targeting aVß1/aVß6 integrin for the treatment of idiopathic pulmonary fibrosis. In addition, the company focuses on immuno-oncology for antibody therapeutics. The company was incorporated in 2013 and is headquartered in South San Francisco, California.